Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Pacific Biosciences of California Inc.

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 20, as revealed in daily fun...

Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS

Pacific Biosciences (($PACB)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Pacific Bios...

Pacific Biosciences’ Earnings Call: Mixed Results and Strategic Outlook

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Thursday, October 30, 2025, reflecting a pullback fr...

Cathie Wood Trims Stakes in 2 Big Tech Stocks, Loads Up on Deere and Pacific Biosciences (PACB)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Wednesday, October 29, according to daily fund ...

Cathie Wood Boosts Biotech and DraftKings Stakes, Trims Shopify

Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Pacific Biosciences today and set a price target of $1.35. The company’s share...

Canaccord Genuity Keeps Their Buy Rating on Pacific Biosciences (PACB)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Friday, October 24, 2025, according to ARK’s daily t...

Market Cap	$498.15M	P/E Ratio	N/A
52W High	$2.46	52W Low	$0.85
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-8.3%	52W Position	85.1%
Overall Score	65	Value Score	40
Quality Score	--	Technical Score	90

EPS Current Est	$-0.54	EPS Next Est	$-0.44
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PACB	$2.22	+18.09%	21.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PACB	$2.22	+18.1%	21.17M
3
4
5
6

PACB

PACB

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Pacific Biosciences of California Inc. Data in Excel

Get Pacific Biosciences of California Inc. Data in Excel